Ｇａｔｉｆｌｏｘａｃｉｎの特別調査中間報告

• 中村 麻子

  杏林製薬株式会社信頼性保証室医薬情報部

• 釜田 美保

  杏林製薬株式会社信頼性保証室医薬情報部

• 池上 泰司

  杏林製薬株式会社信頼性保証室医薬情報部

書誌事項

タイトル別名

• Interim report of special surveys on gatifloxacin

抄録

As the special surveys on gatifloxacin (GFLX), a fluoroquinolone oral antimicrobial agent, we planned to collect 6, 000 patients in order to confirm the safety and efficacy and detect the new problems under conditions of actual use of this product. The target sample size in the first survey was 3, 000 patients.(The second survey is scheduled to be conducted from 2006 to collect 3, 000 patients.) The data collected from 3, 384 patients at 607 sites was compiled to prepare an interim report.<BR>The results showed that 56 (1.66%) of 3, 369 patients eligible for the safety evaluation had experienced a total of 70 adverse reactions. The commonest ADRs were diarrhoea (8 cases), nausea (6 cases) and exanthem (5 cases). At the same time, the new problems were not detected.<BR>The efficacy rate of GFLX in the 3, 212 patients eligible for the efficacy evaluation was 95.3%(observed in 3, 060/3, 212 natients)

収録刊行物

• 日本化学療法学会雑誌

  日本化学療法学会雑誌 53 (12), 748-751, 2005

  公益社団法人 日本化学療法学会

キーワード

• special survey
• gatifloxacin

詳細情報

• CRID: 1390282681261613184
• NII論文ID: 130004298243
• NII論文ID: 10016943229
• NII書誌ID: AN10472127
• DOI: 10.11250/chemotherapy1995.53.748
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/2006104975
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可